Summary

There is a significant unmet clinical need for treatment options for metastatic colorectal cancer (mCRC). This article presents updated overall survival (OS) data from the Patients with Metastatic Colorectal Cancer Treated with Regorafenib or Placebo After Failure of Standard Therapy [CORRECT; NCT01103323] trial. The study demonstrated increased survival benefits following regorafenib treatment in patients with previously treated mCRC.